TPST-1120 is under clinical development by Tempest Therapeutics and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase I drugs for Triple-Negative Breast Cancer (TNBC) have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TPST-1120’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TPST-1120 is under development for the treatment of solid tumors including castration resistant prostate cancer, liposarcoma and leiomyosarcoma, cholangiocarcinoma, gastro-esophageal cancer, head and neck cancer, hepatocellular carcinoma, non-small cell lung cancer, ovarian cancer, pancreatic cancer, renal cell carcinoma, triple-negative breast cancer, urothelial cancer, sarcoma and MSS colorectal cancer. It is a first in class small molecule acts by targeting peroxisome proliferator activated receptor alpha (PPAR alpha). It is administered through oral route.
Tempest Therapeutics overview
Tempest Therapeutics (Tempest) formerly Millendo Therapeutics, Inc. is a biotechnology company. It develops small molecule medicines that regulate anti-tumor immunity pathways. The company’s pipeline portfolio includes TPST-1495, an IDO (enzyme) inhibitor that generates kynurenine, a powerful immunosuppressive factor, which regulates immune cells in the tumor microenvironment (TME) and blocks anti-tumor immunity; TPST-1120, an antagonist that acts against peroxisome proliferator-activated receptor alpha (PPARa); and E-prostanoid (EP) receptor antagonists whose prostaglandin E2 (PGE2) pathway facilitates immune suppression in the TME. Tempest is also developing an orally available inhibitor of TREX-1 designed to activate cGAS/STING pathway, for the development of anti-tumor immunity. TempestTx is headquartered in South San Francisco, California, the US.
For a complete picture of TPST-1120’s drug-specific PTSR and LoA scores, buy the report here.